The steady momentum was largely supported by chronic therapies, including cardiac, anti-diabetic, and central nervous system (CNS) drugs, alongside strong gains in respiratory and oncology.
September 20, 2025In diagnostics, volume growth, better mix, and M&A activity are expected to contribute to a 14 per cent YoY sales increase across the coverage.
July 6, 2025Advertisement